China's Leading Orthopedic Surgical Robot Company Announces Acquisition of Top Implant Manufacturer to Forge Integrated Global Powerhouse

TINAVI, the leading enterprise in China's orthopedic surgical robotics sector, recently announced that it is planning to acquire a controlling stake in Shanghai MicroPort Orthopedics Medical Technology Co., Ltd. ("Shanghai MicroPort Orthopedics") through the issuance of shares. The transaction is expected to constitute a major asset restructuring.

This move has drawn widespread attention from the capital markets, given that TINAVI leads the domestic market share in orthopedic surgical robots, while Shanghai MicroPort Orthopedics ranks among the top in China in terms of revenue. The strategic restructuring of these two companies represents a key step in the integration of the industrial chain within China's intelligent orthopedics sector and will have a profound impact on the industry landscape.

This article analyzes the industry value and market significance of this restructuring from two dimensions: the core drivers of the transaction, and the current development status and trends of the orthopedic surgical robot industry.

As the "first stock of surgical robots" on the STAR Market, TINAVI has been deeply engaged in the field of orthopedic surgical robots for many years. Leveraging its core technological advantages and extensive clinical application experience, it has firmly established itself in the first tier of the domestic industry, with over 49,000 surgical cases performed in 2025.

TINAVI's plan to acquire a controlling stake in Shanghai MicroPort Orthopedics is not merely a capital operation, but an inevitable choice based on the company's long-term development strategy and industry trends. The core drivers can be summarized into three aspects, aiming to achieve multiple breakthroughs in business complementarity, model upgrading, and market expansion.

TINAVI's acquisition of Shanghai MicroPort Orthopedics signals its plan to build a closed-loop ecosystem integrating orthopedic surgical robots with implantable consumables, marking a strategic shift from an open system toward a closed one.

For a long time, whether orthopedic surgical robots should adopt a closed-system business model or an open-system model has been the focus of industry attention.

Comparison of Open and Closed Robotic Systems Data Source: "White Paper on the Development of the Orthopedic Joint Surgery Robotics Industry"

Overseas orthopedic surgical robot companies are mostly giants in the field of orthopedic consumables, and closed systems dominate the international market.

In contrast, early domestic orthopedic surgical robots almost all opted for open systems. Since domestic orthopedic surgical robot manufacturers are independent of orthopedic consumable companies, opting for an open system allows compatibility with a wider range of enterprises. TINAVI's products have also adopted an open system.

However, this industry convention is beginning to loosen. In recent years, more leading orthopedic consumables manufacturers have entered the orthopedic surgical robot market, including AK Medical, Chunli Medical, Sanyou Medical, Double Medical, and Wego Ortho. These companies tend to favor closed systems. VBInsight has learned that companies such as Naton, MicroPort MedBot, Chunli Medical, and AK Medical all prioritize compatibility with their own branded prostheses in the design of joint surgery robots.

As leading domestic orthopedic consumables manufacturers begin to launch integrated solutions, companies with open systems are placed at a disadvantage, and their market space is inevitably compressed. Orthopedic surgical robots must master the supporting implant supply chain to achieve greater development potential.

Perfecting the orthopedic product portfolio and building a comprehensive solution of "robotics + implants + consumables + services" is the core driver behind TINAVI's acquisition of MicroPort Orthopedics.

Shanghai MicroPort Orthopedics, as the core operating entity of MicroPort's overseas orthopedic business, has been deeply engaged in the orthopedic field for over a decade. Its primary business focuses on the research and development, manufacturing, and sales of orthopedic implants, including hip and knee prostheses. With a comprehensive portfolio of implant products and millions of clinical implantation cases, the company boasts strong technical capabilities and a reputable product brand, maintaining significant competitiveness in overseas markets.

Upon completion of this acquisition, TINAVI will officially address its shortcomings in the orthopedic implants and consumables sector. It will transition from a single-provider of surgical robotic equipment to a comprehensive solution provider covering "robotic equipment + implantable consumables + supporting services," thereby establishing a complete closed-loop ecosystem for orthopedic diagnosis and treatment. This ecosystem-oriented layout will better meet the one-stop procurement needs of medical institutions, enhance customer stickiness, and achieve technological integration through product synergy, ultimately delivering more precise and efficient intelligent orthopedic diagnostic and treatment solutions for clinical practice.

Amid the increasingly fierce competition in the domestic market for orthopedic surgical robots, expanding into overseas markets and tapping into global growth opportunities have become key strategic directions for industry leaders.

Although TINAVI has previously held a leading position in the domestic market, its overseas expansion remains in the early stages, lacking mature sales networks and market channels, which poses numerous challenges to its internationalization process.

Shanghai MicroPort Orthopedics has a global DNA. Wright Medical, a subsidiary of Shanghai MicroPort Orthopedics, boasts over 60 years of history in joint reconstruction. Its product portfolio includes hip and knee implants, as well as SuperPath minimally invasive hip surgery instruments. The flagship Axial Knee system has more than 20 years of clinical application history, with over one million implants performed globally, demonstrating a solid foundation in clinical practice and broad market recognition.

Shanghai MicroPort Orthopedics, after years of strategic development, has established a mature and large-scale overseas sales network and customer base in developed countries and regions such as the United States, Japan, and Europe. The company maintains stable cooperative relationships with multiple local medical institutions and distributors, demonstrating a profound understanding of regulatory policies, clinical demands, and consumer habits in the global orthopedic market.

The overseas market for orthopedic surgical robots offers substantial growth potential. Penetration rates are higher in international markets; according to IQVIA data, the penetration rate of orthopedic surgical robots in knee arthroplasty procedures in the United States reached 34.0% in 2024, while it stood at 10% for hip arthroplasty procedures.

Overseas orthopedic surgical robots have also produced blockbuster products. As of 2025, Stryker's star product, the "MAKO" orthopedic surgical robot, has been iterated to its fourth generation and integrated with spinal and shoulder joint functions. With over 3,000 units installed globally and more than 2 million procedures performed, it has effectively driven sales of its proprietary prosthetics.

Previously, MicroPort Medical Group has validated the capability of its overseas markets to drive surgical robot sales through implant distribution channels. MicroPort's Honghu orthopedic surgical robot has achieved steady growth in overseas sales, with global cumulative orders exceeding 65 units and cumulative commercial installations surpassing 50 units.

MicroPort Robotics stated in its annual report that the rapid expansion of the Honghu orthopedic surgical robot in overseas markets was achieved by fully leveraging synergies with the MicroPort Medical Group.

Through this restructuring, TINAVI will directly gain access to Shanghai MicroPort Orthopedics' overseas channel resources and market expertise, enabling rapid entry into mature orthopedic markets in Europe, the United States, and Japan, thereby significantly shortening the timeline for overseas market expansion. Meanwhile, leveraging its comprehensive product advantage of "robotics + implants," TINAVI can better align with the demand for high-end intelligent orthopedic products in international markets, enhance its global competitiveness, promote Chinese-made intelligent orthopedic equipment worldwide, and achieve a leap from being a "domestic leader" to an "international brand."

From a business model perspective, orthopedic surgical robots are low-frequency, high-unit-price equipment products with long sales cycles and substantial capital investment. Their revenue model is relatively singular, making them susceptible to industry policy changes and fluctuations in market demand.

Orthopedic implants and consumables are high-frequency, recurring consumer products. The long-term demand for consumables during patients' postoperative recovery generates stable and continuous cash flow for companies, effectively offsetting the cyclical fluctuations in equipment sales.

Upon completion of this acquisition, TINAVI will achieve an organic integration of "one-time equipment sales" and "recurring revenue from consumables and services," thereby optimizing its profit structure and enhancing the stability and sustainability of its earnings. This upgrade in business model will not only strengthen the company's resilience against market risks but also align its core operational model with those of international orthopedic giants such as Stryker and Johnson & Johnson, injecting new momentum into its long-term performance growth.

Meanwhile, by integrating the R&D, production, and sales resources of both parties, economies of scale can be achieved, reducing production and operational costs, thereby further enhancing the company's profitability and market competitiveness.

The restructuring between TINAVI and MicroPort Orthopedics is essentially a microcosm of the rapid development of the orthopedic surgical robot industry and the accelerated integration of its industrial chain.

In recent years, driven by multiple factors including policy support, an aging population, and technological iteration and upgrades, China's orthopedic surgical robot industry has entered a phase of rapid development. The market size continues to expand, the industry landscape is constantly optimizing, and numerous distinct development characteristics and trends have emerged.

Policy-driven acceleration of hospital adoption: In January 2026, the National Healthcare Security Administration issued project establishment guidelines, categorizing surgical robot-assisted procedures into four tiers—navigation, participatory execution, precise execution, and remote surgery—and implementing a coefficient-based pricing model to guide the application of this technology in complex surgeries. Provinces such as Hunan and Guangdong have taken the lead in publicizing charging standards, specifying the additional fees and price ranges (upper and lower limits) for each tier. These policies have cleared the final barriers to the adoption of surgical robots in hospitals.

Driven by both policy and demand, the domestic market for orthopedic surgical robots is experiencing rapid growth. According to MedRobot statistics, sales of orthopedic surgical robots in China reached no fewer than 168 units in 2025 (compared to 94 units in 2024). The statistical scope includes "publicly announced bid award data from domestic public hospitals + sales data from other domestic channels for selected Chinese manufacturers + overseas sales data for selected Chinese manufacturers."

Currently, the domestic orthopedic surgical robot industry has formed a competitive landscape characterized by "leadership from key players and breakthroughs across multiple fronts." As the first company in China to achieve commercial deployment of orthopedic surgical robots, TINAVI leverages its technological accumulation, clinical data, and market channel advantages to maintain a leading position in the fields of spinal and joint surgical robots, with its market share firmly ranking first in the industry. In addition to TINAVI, other domestic medical device companies such as Tuodao Medical, MicroPort Medical, Wego, and Sanyou Medical have also entered the orthopedic surgical robot sector. Through independent R&D and collaborative efforts, these companies have launched relevant products, gradually forming a competitive market dynamic.

From the perspective of industry development trends, supply chain integration has become a key pathway to enhancing corporate core competitiveness. The orthopedic surgical robotics industry spans multiple fields, including robotics, medical imaging, orthopedic implants, and clinical diagnosis and treatment, making it difficult for any single enterprise to establish an absolute advantage across all segments. Consequently, companies within the industry are increasingly leveraging mergers and acquisitions, strategic partnerships, and other methods to integrate upstream and downstream supply chain resources, thereby achieving synergistic effects in technology, products, and distribution channels.

TINAVI's acquisition of a controlling stake in Shanghai MicroPort Orthopedics is a typical manifestation of the trend toward industry chain integration. In the future, as competition intensifies, more companies are expected to leverage such integration to optimize their product portfolios and enhance overall competitiveness. This will further increase industry concentration, making the advantages of leading enterprises even more pronounced.

From an industry perspective, this restructuring not only reflects the trend of supply chain integration in the orthopedic surgical robotics sector but will also drive technological convergence and product upgrades in China's intelligent orthopedics field, helping Chinese-made high-end medical equipment expand into global markets.